Concomitant use may cause hyperresponse in gastrin secretion, falsely suggesting gastrinoma. Discontinue at least 2 days before Human Secretin administration.
Source: NLP:human secretin
Brand names: Chirhostim, Chirhostim 40
Route: Intravenous
Contraindications
CONTRAINDICATIONS None. None (4)
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary There are no available data (either clinical studies or postmarketing reports) of use of synthetic human secretin in pregnant women. Animal reproduction studies have not been conducted with synthetic human secretin. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
1 interaction on record
Concomitant use may cause hyperresponse in gastrin secretion, falsely suggesting gastrinoma. Discontinue at least 2 days before Human Secretin administration.
Source: NLP:human secretin